Insulin Detemir

證據等級: L5

預測適應症: 10 個

Insulin Detemir: From Global Diabetes Standard Therapy to Type 1 Diabetes Mellitus

One-Sentence Summary

Insulin detemir (Levemir®) is a long-acting basal insulin analogue developed by Novo Nordisk, approved by the FDA (2005) and EMA (2004) as a cornerstone treatment for type 1 and type 2 diabetes mellitus, but currently not registered in Australia with zero ARTG entries. The TxGNN model ranks it as a strong candidate for Type 1 Diabetes Mellitus with a prediction score of 99.77%, supported by 50+ clinical trials and 19 publications — reflecting a mature global evidence base rather than a novel repurposing hypothesis. For Australian healthcare professionals, this report evaluates whether existing global evidence is sufficient to support a local TGA registration pathway, addressing a genuine access gap.

Quick Overview

Item	Content
Original Indication	No ARTG registration; globally approved for type 1 and type 2 diabetes mellitus (FDA 2005, EMA 2004)
Predicted New Indication	Type 1 Diabetes Mellitus
TxGNN Prediction Score	99.77%
Evidence Level	L1
Australia Market Status	Not Marketed
Number of ARTG Entries	0
Recommended Decision	Proceed with Guardrails

Why is This Prediction Reasonable?

Detailed mechanism of action data is not available from the current Evidence Pack. Based on established pharmacological knowledge, insulin detemir is a soluble long-acting human insulin analogue in which the B29 lysine residue is acylated with a C14 fatty acid (myristic acid). Following subcutaneous injection, this modification enables reversible albumin binding and self-association at the injection site, creating a subcutaneous depot that provides gradual and sustained insulin release over 16–24 hours with a relatively flat and predictable pharmacokinetic profile — significantly more consistent than Neutral Protamine Hagedorn (NPH) insulin.

Type 1 Diabetes Mellitus (T1DM) is characterised by autoimmune destruction of pancreatic β-cells, resulting in absolute insulin deficiency. Patients require lifelong exogenous insulin replacement. Insulin detemir directly addresses this pathophysiology by providing basal insulin coverage that mimics physiological inter-prandial and overnight insulin secretion. This is not a novel repurposing hypothesis — it represents the drug’s core global indication. The TxGNN knowledge graph’s high prediction score (99.77%) and top ranking reflect the deeply embedded disease–drug relationships derived from decades of global clinical trials and pharmacological literature.

The clinical relevance for Australia is straightforward: insulin detemir is absent from the Australian register (zero ARTG entries), creating a documented access gap for an internationally accepted standard-of-care basal insulin. Australian patients with T1DM — including pregnant women and children, both populations with dedicated Phase 3 data — may benefit from this agent’s unique albumin-binding pharmacokinetic profile and its well-characterised reduced nocturnal hypoglycaemia profile compared to NPH insulin. The TxGNN prediction essentially confirms what international regulatory bodies have already established, making this primarily a registration pathway question rather than a scientific question.

Clinical Trial Evidence

Trial Number	Phase	Status	Enrolment	Key Findings
NCT00474045	Phase 3	Completed	470	Multinational RCT (Africa, Europe, Americas, Oceania) comparing insulin detemir vs NPH insulin (both with insulin aspart bolus) in pregnant women with T1DM; directly evaluates blood glucose control and maternal/foetal safety — highest-priority population for Australian clinical practice
NCT00095082	Phase 3	Completed	447	Head-to-head comparison of insulin detemir + insulin aspart vs insulin glargine + insulin aspart in basal/bolus therapy for T1DM (Europe and USA); tests non-inferiority and supports positioning relative to glargine
NCT01074268	Phase 3	Completed	456	BEGIN BB T1 trial: insulin degludec vs insulin detemir (both with insulin aspart) in T1DM; multinational including Asia, Europe, and Japan; 12-month follow-up with extension; provides contemporary head-to-head benchmark against a second-generation basal insulin
NCT00435019	Phase 3	Completed	348	Efficacy and safety of insulin detemir vs NPH insulin in European children and adolescents with T1DM using basal-bolus regimen with insulin aspart; key paediatric evidence
NCT00271284	Phase 3	Completed	88	Crossover RCT comparing insulin glargine vs insulin detemir (both with insulin glulisine bolus) in T1DM; primary endpoint: fasting blood glucose variability — directly addresses the predictability advantage of insulin detemir
NCT00773279	Phase 3	Completed	242	Crossover trial assessing blood glucose control with insulin detemir/aspart delivered via PDS290 pen (FlexTouch®) vs FlexPen® in T1DM and T2DM patients in the USA; includes patient preference questionnaires — supports device acceptability data
NCT00117780	Phase 4	Completed	520	European multicentre study comparing insulin detemir once daily vs twice daily as basal insulin in T1DM; endpoints include HbA1c reduction and hypoglycaemia incidence — addresses real-world dosing flexibility
NCT00700765	Observational	Completed	1,531	Asian observational safety study evaluating adverse event incidence with Levemir® in insulin-dependent T1DM and T2DM under routine clinical practice; large real-world safety dataset (Grade B evidence)
NCT00704574	Observational	Completed	159	PREDICTIVE™-Youth: European observational study monitoring serious adverse drug reactions in children and adolescents with T1DM during Levemir® treatment; specific paediatric safety data
NCT00623194	Phase 3	Completed	146	52-week multinational extension study assessing long-term safety of continuous insulin detemir treatment in T1DM children and adolescents aged 3–17 years, including antibody development monitoring

Note: No ANZCTR (Australian New Zealand Clinical Trials Registry) or ICTRP regional trial records were identified for insulin detemir in T1DM. All available trial data is from ClinicalTrials.gov (US registry).

Literature Evidence

PMID	Year	Type	Journal	Key Findings
36623517	2023	RCT (head-to-head)	Lancet Diabetes & Endocrinology	EXPECT trial: multinational open-label non-inferiority RCT comparing insulin degludec vs insulin detemir (both with insulin aspart) in pregnant women with T1DM; provides the most contemporary benchmark for detemir in this high-risk population
29477399	2018	Systematic Review + Network Meta-analysis	Value in Health	Network meta-analysis of basal insulin regimens in adults with T1DM; compares insulin detemir head-to-head against glargine, degludec, and NPH across the full evidence base — key reference for relative positioning
36763996	2022	Systematic Review / Meta-analysis	Clinical Therapeutics	Quantitative synthesis comparing insulin degludec vs insulin glargine and insulin detemir in T1DM and T2DM; provides pooled estimates for HbA1c outcomes, hypoglycaemia rates, and tolerability
21878861	2011	Systematic Review / Meta-analysis	Polskie Archiwum Medycyny Wewnętrznej	Meta-analysis of insulin detemir vs NPH insulin specifically in T1DM; evaluates consistency of glycaemic control improvement findings across individual trials
37290466	2023	Clinical Review / Practice Update	Lancet Diabetes & Endocrinology	Comprehensive update on T1DM management in pregnancy including pharmacological treatment and diabetes technology; discusses time-in-range targets (>70% TIRp 3.5–7.8 mmol/L) and role of basal insulin analogues including detemir
23110609	2012	Drug Review	Drugs	Comprehensive review of insulin detemir in T1DM and T2DM management; covers mechanism of protracted action (albumin binding, self-association), pharmacokinetic variability data, and clinical evidence for hypoglycaemia reduction
17326333	2006	Clinical Review	Vascular Health and Risk Management	Pharmacological review of insulin detemir; describes unique albumin-binding mechanism, reduced intrapatient variability vs NPH and insulin ultralente, and clinical benefits including reduced nocturnal hypoglycaemia in T1DM
20539842	2010	Clinical Review	Vascular Health and Risk Management	Update on detemir’s role in T1DM and T2DM; reports comparable HbA1c control to NPH with lower hypoglycaemia risk and favourable weight profile compared to other basal insulins
15516157	2004	Drug Review	Drugs	Foundational review of insulin detemir at time of original regulatory approval; covers pharmacokinetics, pharmacodynamics, and phase 2/3 clinical evidence in T1DM and T2DM — historical context for the evidence dossier
18454569	2008	Paediatric Review	Paediatric Drugs	Review of insulin analogue preparations in T1DM children and adolescents including insulin detemir; addresses paediatric pharmacokinetic considerations and safety profile

Australia Market Information

Insulin detemir is currently not registered in Australia and has no ARTG entries. No TGA-approved Product Information (PI) or Consumer Medicine Information (CMI) exists for this product locally.

ARTG Number	Product Name	Dosage Form	Approved Indication
—	Not registered	—	No Australian registration. Refer to FDA Prescribing Information (USA) or EMA Summary of Product Characteristics (EU) for reference product information.

Healthcare professionals requiring product information should consult:

USA: FDA-approved Prescribing Information for Levemir® (Novo Nordisk)

EU: EMA-approved Summary of Product Characteristics for Levemir®

Safety Considerations

Please refer to the FDA-approved Prescribing Information (USA) or EMA-approved Summary of Product Characteristics (EU) for complete safety information, as no TGA-approved Product Information is currently available for this product in Australia. No drug interaction data was returned from the local DDI database for this query.

Conclusion and Next Steps

Decision: Proceed with Guardrails

Rationale: Insulin detemir has an exceptionally strong global evidence base including multiple completed Phase 3 randomised controlled trials across adult, pregnant, and paediatric T1DM populations (Evidence Level L1), supported by FDA and EMA approval. Its absence from the Australian ARTG represents a genuine patient access gap for an internationally accepted standard-of-care long-acting insulin analogue, making the TGA registration pathway the appropriate next step rather than further clinical investigation.

To proceed, the following is needed:

TGA regulatory submission: Prepare a complete dossier referencing existing Phase 3 data (NCT00474045, NCT00095082, NCT01074268, NCT00435019 and others) via the standard TGA registration pathway for biological products; explore Category 1 application given extensive international regulatory precedent
Mechanism of action documentation: Obtain full MOA data from DrugBank (DB01307) for inclusion in the Australian PI and CMI documents
Local Product Information and CMI: Draft TGA-compliant PI and CMI documents; adapt FDA/EMA-approved content to meet Australian regulatory format requirements
Safety monitoring plan: Develop risk management strategy for high-risk subpopulations with specific Australian context — pregnant women with T1DM, paediatric patients (3–17 years), and the elderly
Cold-chain supply and GMP compliance: Confirm cold-chain distribution arrangements and manufacturing site compliance with TGA Good Manufacturing Practice requirements
PBS listing pathway assessment: Evaluate pathway for Pharmaceutical Benefits Scheme (PBS) listing; insulin products may qualify for streamlined listing given established clinical need and existing international reimbursement precedent
Healthcare professional training materials: Prepare educational materials on correct injection technique, dose titration, and hypoglycaemia management specific to the Australian clinical context
Disclaimer

This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.